CD8+ tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival.,Clinical & Translational Immunology

当前位置： X-MOL 学术 › Clin. Transl. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

CD8+ tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival.
Clinical & Translational Immunology ( IF 4.6 ) Pub Date : 2020-07-17 , DOI: 10.1002/cti2.1155
Rosemary Millen _{1,

2,

3} , Shona Hendry _{4,

5} , Vignesh Narasimhan _{1,

2} , Rebecca Abbott _{1,

2} , Matthew Croxford ₆ , Peter Gibbs _{7,

8} , Jeanne Tie _{1,

2,

6,

7,

8} , Hui-Li Wong _{7,

8} , Ian Jones ₇ , Suzanne Kosmider _{6,

7} , David Byrne _{1,

2} , John Zalcberg _{9,

10} , Stephen Fox _{1,

2} , Jayesh Desai _{1,

2} , Kumar Visvanathan _{3,

11} , Robert G Ramsay _{1,

2} , Ben Tran _{1,

2,

7,

8}

Affiliation

Tumor‐infiltrating lymphocytes (TIL), particularly CD8⁺ TILs in patients with colorectal cancer (CRC), are highly prognostic in the early‐disease stages (I‐II). In metastatic disease (stage IV; mCRC), their influence is less well defined. It has presumably failed to contain tumor cells to the primary site; however, is this evident? We explored the prognostic impact of TILs at the primary site in patients who presented de novo with mCRC.

中文翻译：

同步性新发转移性结直肠癌患者原发肿瘤内的 CD8+ 肿瘤浸润淋巴细胞不随生存而变化。

肿瘤浸润淋巴细胞 (TIL)，特别是结直肠癌 (CRC) 患者中的CD8 ^{+ TIL，在疾病早期阶段具有高度预后作用 (I-II)。}在转移性疾病（IV 期；mCRC）中，它们的影响尚不明确。它可能未能将肿瘤细胞限制在原发部位；然而，这明显吗？我们探讨了原发部位 TIL 对新发mCRC患者的预后影响。

更新日期：2020-07-18

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文